ESR2 overexpression is very frequent in pulmonary sclerosing hemangiomas, and is similar to alveolar cells but quite different from non-small cell carcinoma.

nongenomic ERbeta has a role in the development of smoking-associated lung cancer

Loss of estrogen receptor beta expression in poorly differentiated (G3) tumors could represent a crucial step in the dedifferentiation process of lung adenocarcinoma.

Results suggest that that proliferative effects of estrogen in lung cancer cells is mediated primarily, if not exclusively, by the nongenomic action of estrogen receptor beta.

Nuclear localization of P-ser118-ER alpha provides one explanation for sex-dependent differences in E(2)-genomic responses in lung adenocarcinoma cell lines.

Estrogen receptor alpha and beta expression distinguishes a subset of NSCLC that has defined clinicopathologic and genetic features. In lung adenocarcinoma, estrogen receptor alpha expression correlates with EGFR mutations.

frequent coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer might suggest some functional correlation between aromatase and estrogen receptor beta

the expression status of ER beta can be a candidate surrogate marker for EGFR-TKI treatment of patients with adenocarcinoma of the lung.

ESR2 is not associated with risk of lung cancer in women

The lung tumors with high ERbeta-1 may define patients with aggressive biology.

A direct association between EGFR mutations and ER beta expression in lung cancer cell lines is lacking.

higher levels of expression in conjunction with higher aromatase levels predict worse survival in non-small cell lung cancer

Activation of the signal transducer and activator of transcription 3 pathway up-regulates estrogen receptor-beta expression in lung adenocarcinoma cells

The median time of survival in patients with lung cancer depending on the expression of ER alpha was 31 months, while for ER beta was 73 months.

The results suggest a differential impact of ER-beta 1 expression on clinical outcome by disease stage in early versus metastatic non-small cell lung cancer.

ERbeta may contribute to non-small cell lung carcinoma via non-genomic action of estrogen through its cytoplasmic form.

No association was found between ER beta polymorphisms and lung cancer in Singapore Chinese women.

Estradiol induces the expression of midkine protein in lung cancer cells through the estrogen receptor beta activation pathway

Case Report: rapidly growing lung adenocarcinoma expressing estrogen receptor beta found during pregnancy.

This is the first study to uncover the expression of ERbeta1, ERbeta2, and ERbeta5, and show that they were over expressed in non small cell lung cancer.

Inherited variability in ESR2 may determine ERb lung tumor expression.

estrogen receptor beta expression in the tissues of non-small cell lung carcinoma and lung metastases of tumors of other primary localizations

high levels of ERbeta-mediated bioactivity in serawere associated with worse prognosis in Chinese postmenopausallung cancer patients independent of estradiol levels.

Estrogen receptor beta 2 regulates IL12RB2 expression via p38 MAPK signaling and inhibits non-small-cell lung cancer proliferation and invasion.

overexpressed in non-small cell lung carcinoma

Estrogen receptor Beta-positive cases of squamous cell lung carcinoma were at risk for poor outcome.

Membrane estrogen receptor beta and GPER signaling mediate cellular responses to environmentally relevant concentrations of CdCl2 and NaAsO2 in lung adenocarcinoma cells.

Results provide evidence for the involvement of ERb1 in the mechanism that regulates DNA damage response in non-small cell lung cancer cells.

Estrogen receptor beta1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.

the obtained results suggest that ERbeta5 and EGFR synergistically promote the progression of lung cancer by activating MEK/ERK signalling pathway, which provides a theoretical basis for more accurate combined targeted therapy.

Nuclear expression of ER - beta was more frequently observed in early stage Non-small Cell lung cancer in never-smokers.

The protein expression of ERbeta was found to be higher in lung adenocarcinoma tissues compared with that in adjacent noncancerous tissues. Of note, ERbeta protein expression was significantly correlated with tumor size, lymph node metastasis, clinical stage and differentiation. In addition, ERbeta protein expression in A549 cells was found to be higher compared with that in human bronchial epithelial cells.

decreased expression of ERbeta protein with increasing tumor grade in non-small cell lung cancer

Oestrogen actions contribute to female gender-specific risks in the development of lung carcinoma.

Estrogen Receptor beta Is Involved in Acquired Resistance to EGFR-tyrosine Kinase Inhibitors in lung cancer.